5448W-13: Mease Pfizer A3921125

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)

Type of Study
Rheumatology - Psoriatic Arthritis
Short Description

To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.


Status
Open
Principal Investigator
Philip J. Mease, MD
Eligibility Notes

Inclusion Criteria:

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
  • Active plaque psoriasis at screening
  • Inadequate efficacy or lack of toleration to previously administered TNF inhibitor

Exclusion Criteria:

  • Non-plaque forms of psoriasis (with exception of nail psoriasis)
  • History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA
Start Date
9/11/2013
Contact Name
Allison Everett
Phone
206-386-3201
Alternate Phone
206-386-6248
Email
Allison.Everett@swedish.org
Alternate Email
Sephren.Barrow@swedish.org